[go: up one dir, main page]

AR052995A1 - Compuestos de 3h-oxazolo y 3h-tiazolo[4, 5 - d]pirimidin-2-ona3, 5-disustituidos y 3, 5, 7-trisustituidos con actividad inmunomoduladora, sus profarmacos, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de enfermedades de origen viral - Google Patents

Compuestos de 3h-oxazolo y 3h-tiazolo[4, 5 - d]pirimidin-2-ona3, 5-disustituidos y 3, 5, 7-trisustituidos con actividad inmunomoduladora, sus profarmacos, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de enfermedades de origen viral

Info

Publication number
AR052995A1
AR052995A1 ARP050105306A ARP050105306A AR052995A1 AR 052995 A1 AR052995 A1 AR 052995A1 AR P050105306 A ARP050105306 A AR P050105306A AR P050105306 A ARP050105306 A AR P050105306A AR 052995 A1 AR052995 A1 AR 052995A1
Authority
AR
Argentina
Prior art keywords
alkyl
nhc
heterocyclyl
aryl
cycloalkyl
Prior art date
Application number
ARP050105306A
Other languages
English (en)
Inventor
S E Webber
G J Haley
J R Lennox
A X Xiang
E J Rueden
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of AR052995A1 publication Critical patent/AR052995A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y su profármacos que tienen actividad inmunomoduladora, uso terapéutico o preventivo de tales compuestos y composiciones farmacéuticas que los contienen y se emplea en el tratamiento de enfermedad de origen viral. Reivindicacion 1: Un compuesto de la formula (1), en donde: X es O o S, Y es O o S, R1 es H, alquilo, arilo, cicloalquilo o heterociclilo; R2 es NH2, -NHC(O)R4, -NHR5, - N=CHNR6R7, R3 es H, Cl, Br, u OR8, R4 es -alquiloC1-7 u -OalquiloC1-7, R5 es -alquiloC1-7; R6 y R7 son, de modo independiente, -alquiloC1-7 o junto con nitrogeno forman un anillo heterocíclico de 5 o 6 miembros; R8 es -CHR9R10; R9 es H, -alquiloC1- 7, cicloalquilo, arilo, heterociclilo, -NR11R12, u OR5; R10 es -alquiloC1-7, cicloalquilo, arilo, heterociclilo, -NR11R12, u OR5; R11 y R12 son, de modo independiente, H, -alquiloC1-7 o -C(O)R4; en donde, cuando X es O, Y es S, y R3 es H, Cl, Br, u OR8, R1 no es H o beta-D-ribosa o sus ésteres; en donde los restos anteriores de alquilo, arilo, cicloalquilo o heterociclilo están opcionalmente sustituidos con 1-4 sustituyentes seleccionados de hidrogeno; alcanoilo; alquilamina; amino; arilo, cicloalquilo, heterociclilo; azido; alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, alquilamina C1-6, dialquilamina C1-6, alquenilo C2-6 o alquinilo C2-6, en donde cada uno de los cuales puede estar interrumpido por uno o varios heteroátomos; carboxilo; ciano; halo; hidroxi; mercapto; nitro; tioalquilo; -N=N-NH2; -C(O)2-alquiloC1-6, -C(O)2-arilo, -C(O)2-cicloalquilo, -C(O)2-heterociclilo, -O-haloalquiloC1-6, -O-(alquil C1-6l)arilo, -O-(alquil C1-6)cicloalquilo, -O-(alquil C1-6)heterociclilo, -O-(alquil C1-6)amino, -O-(alquil C1-6)alquilamino, -O-(alquil C1-6)dialquilamino, -O-alquilC1-6-C(O)-amino, -O-alquilC1-6-C(O)-alquilamino, -O-alquilC1-6-S(O)2-amino, -O-alquilC1-6-S(O)2-alquilamino, -O-alquilC1-6-S(O)2- dialquilamino, -O-alquilC1-6-C(O)-dialquilamino, -O-arilo, -O-heterociclilo, -NHC(O)-alquiloC1-6, -NHC(O)-alqueniloC1-6, -NHC(O)-arilo, -NHC(O)-cicloalquilo, -NHC(O)-heterociclilo, -NHC(O)-(alquil C1-6)arilo, -NHC(O)-(alquil C1-6)cicloalquilo, - NHC(O)-(alquil C1-6)heterociclilo, -NHC(O)-(alquil C1-6)amino, -NHC(O)-(alquil C1-6)alquilamina, -NHC(O)-(alquil C1-6)dialquilamina, -NHC(O)-alquilC1-6C(O)amino, -NHC(O)-alquilC1-6C(O)alquilamina, -NHC(O)-alquilC1-6C(O)dialquilamina, -NHC(O)- alquilC1-6N(H)-alquilC1-6C(O)2-alquiloC1-6, -NH-alquilC1-6-C(O)-amino, -NH-alquilC1-6-C(O)-alquilamino, -NH-alquilC1-6-C(O)-dialquilamino, -NHC(O)-alquilC1-6S(O)2alquiloC1-6, -NHC(O)-alquilC1-6-S-heterociclilo, -NHS(O)2-alquiloC1-6, -NHS(O)2-arilo, - NH-alquilC1-6-S(O)2-amino, -NH-alquilC1-6-S(O)2-alquilamino, -NH-alquilC1-6-S(O)2-dialquilamino, -NHS(O)2-cicloalquilo, -NHS(O)2-heterociclilo, -NHS(O)alquiloC1-6, -NHS(O)arilo, -NHS(O)cicloalquilo, -NHS(O)heterociclilo, -NHSalquiloC1-6, -NHSarilo, - NHScicloalquilo, y -NH-S-heterociclilo; en donde cada uno de los sustituyentes anteriores pueden estar además opcionalmente sustituidos con 1-5 sustituyentes seleccionados de: amino; alquilamina C1-6, dialquilamina C1-6; alquilo C1-6, alcoxi C1-6, alquenilo C1-6, hidroxilo C1-6, e hidroxialquilo C1-6, cada uno opcionalmente sustituido con: ciano; halo; y nitro; o una de sus sales o hidratos farmacéuticamente aceptables. Reivindicacion 8: Un compuesto de la formula (2), en donde: X es O o S, Y es O o S, Z es O o CH2; R2 es -NH2, -NHC(O)R4, -NHR5, -N=CHNR6R7, R4 es -alquiloC1-7 u -OalquiloC1-7, R5 es -alquiloC1-7; R6 y R7 son, de modo independiente, -alquiloC1-7 o junto con nitrogeno forman un anillo heterocíclico de 5 o 6 miembros; R13 es OH o SH; R14 es H, -CH2OH o -CH2-O-C(O)alquiloC1-18; R15 es OH, alquenilo, -OC(O)alquiloC1-18, -OC(O)arilo u -OC(O)heterociclilo; R16, 17, R18, y R19 son, de modo independiente, H, halo, N3, alquilo, -(CH2)mOR20, -(CH2)mOC(O)alquiloC1-18, - OC(O)arilo, -OS(O)2arilo o R16 y R17 son un alquenilo o R17 y R19 se combinan para formar un anillo dioxol; R20 es H o alquilo; m es 0 o 1; n es 1 o 2; en donde cuando R2 es NH2, entonces uno de los siguientes debe estar presente: Z es CH2; n es 2 o m es 1; al menos de R16, R17, R18, y R19 es halo, N3, alquilo o -(CH2)mOR20, en donde m es 1, y en donde cuando R17 es N3, entonces R18 y R19 no son H, y en donde cuando R17 es OH y R16 y R19 son H, R18 no es F; o R16 y R17 son un alquenilo; en donde los restos de alquilo, arilo, cicloalquilo o heterociclilo están opcionalmente sustituidos con 1-4 sustituyentes seleccionados de hidrogeno; alcanoilo; alquilamina; amino; arilo, cicloalquilo, heterociclilo; azido; alquilo C1-6, haloalquilo C1- 6, hidroxialquilo C1-6, alcoxi C1-6, alquilamina C1-6, dialquilamina C1-6, alquenilo C2-6 o alquinilo C2-6, en donde cada uno de los cuales puede estar interrumpido por uno o varios heteroátomos; carboxilo; ciano; halo; hidroxi; mercapto; nitro; tioalquilo; -N=N-NH2; -C(O)2-alquiloC1-6, -C(O)2-arilo, -C(O)2-cicloalquilo, -C(O)2-heterociclilo, -O-haloalquiloC1-6, -O-(alquil C1-6l)arilo, -O-(alquil C1-6)cicloalquilo, -O-(alquil C1-6)heterociclilo, -O-(alquil C1-6)amino, -O-(alquil C1- 6)alquilamino, -O-(alquil C1-6)dialquilamino, -O-alquilC1-6-C(O)-amino, -O-alquilC1-6-C(O)-alquilamino, -O-alquilC1-6-S(O)2-amino, -O-alquilC1-6-S(O)2-alquilamino, -O-alquilC1-6-S(O)2-dialquilamino, -O-alquilC1-6-C(O)-dialquilamino, -O-arilo, -O- heterociclilo, -NHC(O)-alquiloC1-6, -NHC(O)-alqueniloC1-6, -NHC(O)-arilo, -NHC(O)-cicloalquilo, -NHC(O)-heterociclilo, -NHC(O)-(alquil C1-6)arilo, -NHC(O)-(alquil C1-6)cicloalquilo, -NHC(O)-(alquil C1-6)heterociclilo, -NHC(O)-(alquil C1-6)amino, - NHC(O)-(alquil C1-6)alquilamina, -NHC(O)-(alquil C1-6)dialquilamina, -NHC(O)-alquilC1-6C(O)amino, -NHC(O)-alquilC1-6C(O)alquilamina, -NHC(O)-alquilC1-6C(O)dialquilamina, -NHC(O)-alquilC1-6N(H)-alquilC1-6C(O)2-alquiloC1-6, -NH-alquilC1-6-C(O)-amino, - NH-alquilC1-6-C(O)-alquilamino, -NH-alquilC1-6-C(O)-dialquilamino, -NHC(O)-alquilC1-6S(O)2alquiloC1-6, -NHC(O)-alquilC1-6-S-heterociclilo, -NHS(O)2-alquiloC1-6, -NHS(O)2-arilo, -NH-alquilC1-6-S(O)2-amino, -NH-alquilC1-6-S(O)2-alquilamino, -NH- alquilC1-6-S(O)2-dialquilamino, -NHS(O)2-cicloalquilo, -NHS(O)2-heterociclilo, -NHS(O)alquiloC1-6, -NHS(O)arilo, -NHS(O)cicloalquilo, -NHS(O)heterociclilo, -NHSalquiloC1-6, -NHSarilo, -NHScicloalquilo, y -NH-S-heterociclilo; en donde cada uno de los sustituyentes anteriores pueden estar además opcionalmente sustituidos con 1-5 sustituyentes seleccionados de: amino; alquilamina C1-6, dialquilamina C1-6; alquilo C1-6, alcoxi C1-6, alquenilo C1-6, hidroxilo C1-6, e hidroxialquilo C1-6, cada uno opcionalmente sustituido con: ciano; halo; y nitro; o una de sus sales, hidratos o tautomeros farmacéuticamente aceptables.
ARP050105306A 2004-12-17 2005-12-16 Compuestos de 3h-oxazolo y 3h-tiazolo[4, 5 - d]pirimidin-2-ona3, 5-disustituidos y 3, 5, 7-trisustituidos con actividad inmunomoduladora, sus profarmacos, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de enfermedades de origen viral AR052995A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63663304P 2004-12-17 2004-12-17
US63663404P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
AR052995A1 true AR052995A1 (es) 2007-04-18

Family

ID=36588217

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105306A AR052995A1 (es) 2004-12-17 2005-12-16 Compuestos de 3h-oxazolo y 3h-tiazolo[4, 5 - d]pirimidin-2-ona3, 5-disustituidos y 3, 5, 7-trisustituidos con actividad inmunomoduladora, sus profarmacos, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de enfermedades de origen viral

Country Status (28)

Country Link
US (4) US7560544B2 (es)
EP (2) EP1824482B1 (es)
JP (1) JP5303149B2 (es)
KR (1) KR101320008B1 (es)
CN (1) CN102504001B (es)
AR (1) AR052995A1 (es)
AU (1) AU2005316397B2 (es)
BR (1) BRPI0518861B8 (es)
CA (1) CA2589529C (es)
DK (2) DK1824482T3 (es)
EA (1) EA013594B1 (es)
EG (1) EG25920A (es)
ES (2) ES2525567T3 (es)
GT (1) GT200500374A (es)
IL (2) IL183512A (es)
MX (1) MX2007007263A (es)
MY (1) MY176938A (es)
NO (1) NO20073615L (es)
NZ (1) NZ555723A (es)
PA (1) PA8657201A1 (es)
PE (1) PE20060837A1 (es)
PL (2) PL1824482T3 (es)
PT (2) PT2561872E (es)
SI (2) SI2561872T1 (es)
TN (1) TNSN07208A1 (es)
TW (1) TWI407956B (es)
UY (1) UY29265A1 (es)
WO (1) WO2006066080A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AU2006318260B2 (en) * 2005-11-21 2012-05-17 Anadys Pharmaceuticals, Inc. Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one
US7709448B2 (en) * 2006-06-22 2010-05-04 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
US7528115B2 (en) 2006-07-18 2009-05-05 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines
CN101605457B (zh) * 2006-10-17 2013-10-30 安那迪斯药品股份有限公司 5-氨基-3-(2'-0-乙酰基-3'-脱氧-β-D-呋喃核糖基)-3H-噻唑[4,5-d]嘧啶-2-酮的对甲苯磺酸盐及制备方法
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
US20110166092A1 (en) 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
US8227431B2 (en) * 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
WO2010108140A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
US20130029904A1 (en) 2009-12-18 2013-01-31 Boehringer Ingelheim International Gmbh Hcv combination therapy
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014121416A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US9227718B2 (en) * 2013-06-07 2016-01-05 The Boeing Company Lower joints between outboard wing boxes and center wing sections of aircraft wing assemblies
MA40238A (fr) 2014-07-11 2017-05-17 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
JP2017531655A (ja) 2014-10-11 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染性疾患の処置に使用するための化合物
MA41134B1 (fr) * 2014-12-08 2021-03-31 Hoffmann La Roche Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
RU2718917C2 (ru) * 2015-03-16 2020-04-15 Ф. Хоффманн-Ля Рош Аг Комбинированное лечение агонистом толл-подобного рецептора (tlr7) и ингибитором сборки капсида вируса гепатита в
EP3294745B1 (en) 2015-05-08 2020-01-01 H. Hoffnabb-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
EP4001283A1 (en) * 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
EP3317289B1 (en) 2015-06-30 2021-10-27 F. Hoffmann-La Roche AG Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
WO2017211791A1 (en) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
US11142534B2 (en) * 2017-01-06 2021-10-12 Hoffmann-La Roche Inc. Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
PE20211598A1 (es) * 2018-05-25 2021-08-18 Primmune Therapeutics Inc Agonistas de tlr7
AU2019300324A1 (en) 2018-07-13 2021-01-21 F. Hoffmann-La Roche Ag Oligonucleotides for modulating RTEL1 expression
CA3163093A1 (en) * 2019-11-26 2021-06-03 Primmune Therapeutics, Inc. Tlr7 agonists
MX2022007909A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
CN114846140A (zh) 2019-12-24 2022-08-02 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合
US20240156795A1 (en) * 2020-11-24 2024-05-16 Lankenau Institute For Medical Research Methods and compositions for the treatment of drug resistant topical infections
WO2022197927A1 (en) * 2021-03-18 2022-09-22 Lankenau Institute For Medical Research Methods and compositions for the treatment of drug resistant topical infections
EP4370132A2 (en) * 2021-07-15 2024-05-22 Alnylam Pharmaceuticals, Inc. Multiplexing targeting ligands through click chemistry at the anomeric site of sugars
EP4430184A2 (en) 2021-11-11 2024-09-18 F. Hoffmann-La Roche AG Pharmaceutical combinations for treatment of hbv

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5166141A (en) * 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US4746651A (en) 1983-11-01 1988-05-24 Scripps Clinic And Research Foundation Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8712745D0 (en) 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5041542A (en) 1988-06-03 1991-08-20 Nucleic Acid Research Institute Substituted pyrimido[5,4-d]pyrimidine nucleosides
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9015914D0 (en) 1990-07-19 1990-09-05 Wellcome Found Heterocyclic compounds
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9105899D0 (en) 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1994007904A1 (en) 1992-10-01 1994-04-14 Mcneilab, Inc. Derivatives of 7,8-disubstituted guanosines
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5446045A (en) 1993-12-20 1995-08-29 Revankar; Ganapathi R. Antiviral guanine analogs
US5994321A (en) * 1993-12-20 1999-11-30 Aronex Pharmaceuticals, Inc. Antiviral guanine analogs
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5950619A (en) 1995-03-14 1999-09-14 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
ATE218381T1 (de) 1995-03-14 2002-06-15 Siemens Ag Ultraschall-zerstäuber mit abnehmbarer präzisionsdosiereinheit
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
DE69729887T2 (de) * 1996-10-16 2005-07-28 ICN Pharmaceuticals, Inc., Costa Mesa Purin-L-Nukleoside, Analoga und deren Verwendung
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
EP0938315B9 (en) 1996-10-25 2008-02-20 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
ES2205573T3 (es) 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited Nuevo compuestos heterociclicos.
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
WO1999051608A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US6914068B2 (en) * 2001-07-12 2005-07-05 Basf Aktiengesellschaft Thiazolo[4,5-b]pyridines as fungicides
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
IL162137A0 (en) 2001-11-27 2005-11-20 Anadys Pharmaceuticals Inc D-ribofuranosylthiazolo -3-Ä4,5-dÜpyridimine nucl eosides and uses thereof
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
CN1964985A (zh) * 2004-06-07 2007-05-16 阿纳迪斯药物公司 3－β－D－呋喃核糖基噻唑并[4,5－d]嘧啶核苷类及其应用

Also Published As

Publication number Publication date
CN102504001B (zh) 2015-02-25
US8097718B2 (en) 2012-01-17
PE20060837A1 (es) 2006-09-02
EP1824482B1 (en) 2014-02-12
PL2561872T3 (pl) 2015-03-31
PL1824482T3 (pl) 2014-07-31
AU2005316397B2 (en) 2012-02-02
CA2589529C (en) 2013-09-10
ES2459368T3 (es) 2014-05-09
TW200635588A (en) 2006-10-16
PT1824482E (pt) 2014-05-13
GT200500374A (es) 2006-07-03
TNSN07208A1 (en) 2008-11-21
BRPI0518861B1 (pt) 2021-03-09
BRPI0518861B8 (pt) 2021-05-25
MX2007007263A (es) 2007-08-14
IL220759A0 (en) 2012-08-30
NO20073615L (no) 2007-09-12
MY176938A (en) 2020-08-27
AU2005316397A1 (en) 2006-06-22
US7560544B2 (en) 2009-07-14
DK1824482T3 (en) 2014-03-24
EP1824482A1 (en) 2007-08-29
HK1108377A1 (en) 2008-05-09
IL220759A (en) 2015-07-30
EA200701296A1 (ru) 2007-12-28
EP1824482A4 (en) 2009-08-26
UY29265A1 (es) 2006-07-31
US20130259831A1 (en) 2013-10-03
EP2561872B1 (en) 2014-09-10
EP2561872A1 (en) 2013-02-27
JP5303149B2 (ja) 2013-10-02
BRPI0518861A2 (pt) 2009-03-24
CA2589529A1 (en) 2006-06-22
WO2006066080A1 (en) 2006-06-22
DK2561872T3 (en) 2014-12-08
US20110275589A1 (en) 2011-11-10
SI1824482T1 (sl) 2014-06-30
PA8657201A1 (es) 2006-12-07
IL183512A0 (en) 2007-09-20
ES2525567T3 (es) 2014-12-26
CN102504001A (zh) 2012-06-20
JP2008534437A (ja) 2008-08-28
SI2561872T1 (sl) 2015-02-27
KR101320008B1 (ko) 2013-10-18
KR20070107005A (ko) 2007-11-06
EG25920A (en) 2012-10-15
TWI407956B (zh) 2013-09-11
NZ555723A (en) 2010-07-30
US8883758B2 (en) 2014-11-11
EA013594B1 (ru) 2010-06-30
HK1175990A1 (en) 2013-07-19
US20060160830A1 (en) 2006-07-20
US20120121541A1 (en) 2012-05-17
PT2561872E (pt) 2014-12-18
IL183512A (en) 2013-04-30

Similar Documents

Publication Publication Date Title
AR052995A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo[4, 5 - d]pirimidin-2-ona3, 5-disustituidos y 3, 5, 7-trisustituidos con actividad inmunomoduladora, sus profarmacos, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de enfermedades de origen viral
ES2349110T3 (es) Inhibidores de iap derivadops de pirrolidina.
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR077463A1 (es) Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
AR048241A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
EA200400615A1 (ru) Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета
CA2628131A1 (en) Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
CY1115533T1 (el) Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr
AR083161A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos
BRPI0410714B8 (pt) derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR045082A1 (es) Compuestos de aminobenzofenona y su uso en tratamientos terapeuticos
AR061580A1 (es) Profarmacos de 5- amino-3-(3'- desoxi- beta-d - ribofuronosil)-tiazolo [4 ,5- d] pirimidin-2,7- diona
AR018915A1 (es) Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
CR8756A (es) Derivados de acido carboxilico bencimidazolona
PE55298A1 (es) Derivados de pirrolopirrolona
PE20081492A1 (es) Derivados de sulfonamida heterociclicos como antagonista de edg-1
AR048808A1 (es) Pirrolocarbazoles fusionados
AR005916A1 (es) Compuestos de oxadiazol, y de tiadiazol, su uso, procedimientos para prepararlos, composiciones farmaceuticas que los contienen y un compuesto util como intermedio
ATE338042T1 (de) Hetero-bicyclische crf antagonisten
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
MA33103B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met

Legal Events

Date Code Title Description
FA Abandonment or withdrawal